Trelegy (fluticasone furoate umeclidinium bromide vilanterol trifenatate): Reviews and patient testimonials

/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Medication indications

Trelegy

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist (for effects on symptom control see section 5.1).


Molecule: fluticasone furoate, umeclidinium bromide, vilanterol trifenatate

Patients' opinions on Trelegy

In brief

General satisfaction level: 8.67/10 Learn more

Treatment's effectiveness: 8.67/10 Learn more

Ease of use: 9.33/10 Learn more

Adherence to prescription: 9.67/10 Learn more

Detected side effects: 2.00/10 Learn more

Improvement in the quality of life: 7.67/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community


avatar
Tonypalony
on 06/07/2021

Find that it's easy to use the benefits outweigh any side effects like dry mouth or  oral thrush no other issues found 

Your message


avatar
Mikest
on 07/07/2020

Seems to be a combination of two other inhalers, relvar and incruse,  which I had been using for a couple of years. Touch wood, I haven’t had a COPD flare-up for eight months, which is good, although my shortage pf breath hasn’t improved.

Your message


avatar
nickypage99
on 05/05/2020

Easy to use, seems more effective than previous medication, no side effects

Your message


avatar
Dodger99
on 20/02/2019

Easier to use than some other inhalers, seems effective with no noticeable side effects. 

Your message

Conditions related to this medication

Fact sheet

COPD

See the fact sheet